DOCSLIB.ORG

Outcomes and Risk Score for Distal Pancreatectomy

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

FREE ORALS (FP01-FP31) FP01 e Free papers 1 (mini oral) - Biliary: Introduction: The American Joint Committee on Cancer (AJCC), 8th edition, has revised the T system for distal Cholangiocarcinoma cholangiocarcinoma (DCC) from layer-based to depth- FP01-01 based approach. The aim of this study was to propose an NATIONWIDE TREATMENT, OUTCOME optimal T classification using a measured depth in resect- AND PREDICTORS FOR SURVIVAL IN able DCC. DISTAL CHOLANGIOCARCINOMA Method: Patients who underwent pancreatoduodenectomy for DCC at 32 hospitals between 2001 and 2010 were M. Strijker1, A. Belkouz1, L. G. van der Geest2, included. The distance between the basal lamina and the O. R. Busch1, T. M. van Gulik1, J. Verheij1, advancing cancer cells was measured as depth of invasion J. W. Wilmink1, B. Groot Koerkamp3, H. J. Klümpen1, (DOI). The invasive cancer foci was measured as invasive M. G. Besselink1 and Dutch Pancreatic Cancer Group tumor thickness (ITT). Log-rank c2 was used to determine 1Cancer Center Amsterdam, Academic Medical Center, the cutoff points, and C-index was used to assess the sur- University of Amsterdam, 2Netherlands Comprehensive vival discrimination of each T system. Cancer Organisation (IKNL), and 3Erasmus University Results: Some 404 patients were included. DOI and ITT Medical Center, The Netherlands were measurable in 182 and all patients, and the medians Background: Distal cholangiocarcinoma has a poor were 2.3 and 5.6 mm, respectively. They both showed a prognosis. Published cohorts focusing on distal chol- strong positive correlation (correlation coefficient, 0.854), angiocarcinoma, especially from Western countries, are and the cutoff points of ITT were 1, 5, and 10 mm. The lacking. This study investigated treatment, outcome and median survival time was significantly shortened with in- predictors for survival in a nationwide cohort of patients crease in ITT: 12.4 years for ITT< 1 mm, 5.2 years for with distal cholangiocarcinoma. 1ITT< 5 mm, 3.0 years for 5 ITT< 10 mm, and 1.5 Methods: A population-based cohort derived from the years for ITT10 mm . This 4-tier ITT classification Netherlands Cancer Registry (NCR) was studied. Patients exhibited the most favorable prognostic discrimination, fi with pathologically con rmed distal cholangiocarcinoma, compared to the T systems of AJCC 7th/8th editions (C- resected (2005-2015) and non-resected (2009-2015), were index: 0.6463, 0.6218, and 0.6243). included. Survival was analyzed using Kaplan Meier Conclusions: ITT is a versatile approach for depth methods and multivariable Cox analysis using backward assessment in DCC. The 4-tier ITT classification with selection. cutoff points of 1, 5, and 10 mm can be used as an optimal T fi Results: A total of 794 patients was identi ed; 513 resected system. patients and 321 non-resected patients. Of the resected patients (7.8%) received (neo-)adjuvant treatment. Of 321 non-resected patients, 147 (45.8%) presented with M1 disease and 63 (19.6%) received palliative chemotherapy. FP01-03 Median overall survival for resected, non-resected M0, and EVALUATION OF THE NEW AMERICAN non-resected M1 disease was 23 months (95% CI 21-26), 6 JOINT COMMITTEE ON CANCER months (95% CI 5-8) and 4 months (95% CI 4-5) (p< STAGING MANUAL 8TH EDITION FOR 0.001), respectively. In multivariable analysis, T3/T4 stage PERIHILAR CHOLANGIOCARCINOMA < (p=0.006), higher lymph node ratio (p 0.001), poor dif- 1 1 1 1 ferentiation (p=0.001) and R1 resection (p=0.002) were M. Gaspersz , S. Buettner , J. van Vugt , J. de Jonge , W. Polak1, M. Doukas2, J. Ijzermans1, negative prognostic factors in resected patients. In non- 1 3 resected patients, increasing age (p=0.007), lymph node B. Groot Koerkamp and F. Willemssen 1Surgery, Erasmus MC, University Medical Center metastases (p=0.013), distant metastases (p< 0.001), no Rotterdam, 2Pathology, Erasmus MC, University Medical surgical exploration (p=0.011) and no palliative chemo- Center Rotterdam, and 3Radiology and Nuclear Medicine, therapy (p< 0.001) predicted worse survival. Erasmus MC, University Medical Center Rotterdam, The Discussion: This nationwide, Western study includes the Netherlands largest population with all stages of distal chol- th angiocarcinoma. The study identified predictors for sur- Introduction: To evaluate the 8 edition of the American vival in both the resected and non-resected population Joint Committee on Cancer (AJCC) staging system for which can be useful to stratify future trials with (neo-) perihilar cholangiocarcinoma (PHC), and to compare the th th adjuvant or palliative treatment. prognostic value of the 7 and 8 editions of the AJCC staging system for PHC. Methods: All patients with PHC between 2002-2014 FP01-02 were included. Imaging at the time of presentation was reassessed and AJCC Tumor-Nodal-Metastasis (TNM) PROPOSAL OF AN OPTIMAL DEPTH- stage was determined according to the 7th and 8th edition BASED TUMOR CLASSIFICATION IN of the AJCC staging system. Overall survival (OS) was DISTAL CHOLANGIOCARCINOMA estimated using the Kaplan-Meier method. Comparison H. Aoyama, T. Ebata, Y. Yokoyama, T. Igami, T. Mizuno, of the prognostic accuracy of staging systems was J. Yamaguchi, S. Onoe and M. Nagino performed using the concordance index (c-index) and Nagoya University Graduate School of Medicine, Japan Brier-score. HPB 2018, 20 (S2), S182eS294 Free Orals (FP01-FP31) S183 Results: A total of 248 PHC patients were included. were as good as the prognosis of ICC patients underwent Median OS of the entire cohort was 9.7 months (8.0-11.5). upfront R0 surgery. Prognostic accuracy was comparable between the 7th and Conclusion: If R0 resection is expected, aggressive sur- 8th AJCC staging systems (c-index 0.59 vs 0.58). Prog- gical resection with regional lymph nodes dissection is nostic accuracy of the 8th edition was higher in the sub- recommended in advanced ICC patients with LNM. group of resected patient (0.67), but expanding the staging However, downsizing chemotherapy is useful for patients system with sub-stages lowered the c-index to 0.62. The with initially unresectable locally advanced ICC for prognostic accuracy of the AJCC staging system in unre- improving prognosis. sectable patients was poor with a c-index of 0.57 in both the normal and expanded staging system. th th Conclusions: The 7 and 8 editions of the AJCC staging FP01-05 system for PHC have comparable prognostic accuracy. A COMPARISON OF TREATMENT AND Although developed to be used for resectable and unre- sectable patients, the discriminative performance in unre- OUTCOMES OF PERIHILAR sectable patients was poor. Therefore, the AJCC staging CHOLANGIOCARCINOMA IN AN system may need modifications to improve its prognostic EASTERN AND WESTERN CENTER accuracy in patients with unresectable PHC, compromising P. Olthof1,2, M. Miyasaka3, W. Jarnagin4, the majority of patients. T. van Gulik1 and T. Noij3 1Academic Medical Center Amsterdam, 2Syrgeru, Reinier de Graaf Gasthuis, The Netherlands, 3Hokkaido Univer- FP01-04 sity Graduate School of Medicine, Japan, and 4Memorial MULTIDISCIPLINARY TREATMENT Sloan Kettering Cancer Center, United States COMBINED WITH NEOADJUVANT Background: Perihilar cholangiocarcinoma (PHC) is a rare DOWNSIZING CHEMOTHERAPY AND tumor that requires multimodal multidisciplinary treatment AGGRESSIVE REGIONAL LYMPH and is associated with substantial morbidity and mortality. Treatment strategies and outcomes vary greatly between NODE DISSECTION TO ACHIEVE R0 the eastern and western parts of the world. This study aimed RESECTION IMPROVES PROGNOSIS IN to compare a major eastern and western PHC cohort in PATIENTS WITH ADVANCED terms of patient characteristics, treatment strategies and INTRAHEPATIC outcomes including a propensity score matched analysis. CHOLANGIOCARCINOMA Methods: All consecutive patients who underwent com- bined biliary and liver resection for PHC between 2005 and S. Kuboki, H. Yoshitomi, K. Furukawa, T. Takayashiki, 2016 at two western and one eastern center were included. S. Takano, M. Miyazaki and M. Ohtsuka A propensity score matched analysis based on baseline Department of General Surgery, Graduate School of characteristics to compare perioperative outcomes and a Medicine, Chiba University, Japan multivariable analysis for survival were performed. Background: R0 resection is the only chance for long-term Results: A total of 210 western patients were compared to survival in patients with intrahepatic cholangiocarcinoma 164 eastern patients. After propensity score matching (1:1), (ICC); however, the prognosis of ICC with lymph node the two cohorts both including 79 patients had similar rates metastasis (LNM) is poor and sometimes difficult to of liver failure and morbidity, however biliary leakage achieve R0 resection. (33% versus 17%, p=0.03) and morality rates (18% versus Aim: To evaluate the usefulness of neoadjuvant downsiz- 5%) were higher in the west. Despite matching based on ing chemotherapy and aggressive regional lymph node liver volume, portal vein embolization was more frequent dissection to achieve R0 resection for improving prognosis. in the east (58% versus 11%, p< 0.01). At multivariable Methods: 135 ICC patients underwent R0/R1 resection analysis, western patients had inferior survival compared to were enrolled. For control, 28 locally advanced ICC pa- the east (hazard-ratio 1.72 (1-23-2.40) P < 0.01) corrected tients receiving chemotherapy only (gemcitabine, cispla- for age, ASA score, tumor stage and margin. tine, or S-1) were selected. Discussion: There are major differences in patient charac- Results: Larger tumor size, positive vascular/lymphatic teristics, treatment strategies, perioperative outcomes and invasion, positive intrahepatic metastasis, positive LNM, survival between eastern and western PHC cohorts. These and R1 resection were significant risk factors for poorer results indicate that PHC research should not be translated prognosis. R1 resection was the strongest prognostic across the world before cross-cardinal external validation factor. When prognostic factors in R0 cases were further evaluated, positive LNM was an independent risk factor for poorer prognosis. However, even though LNM FP01-06 existed, aggressive R0 resection improved prognosis.
Recommended publications
  • Endo4 PRINT.Indb

    Endo4 PRINT.Indb

    Contents 1 Tumours of the pituitary gland 11 Spindle epithelial tumour with thymus-like differentiation 123 WHO classifi cation of tumours of the pituitary 12 Intrathyroid thymic carcinoma 125 Introduction 13 Paraganglioma and mesenchymal / stromal tumours 127 Pituitary adenoma 14 Paraganglioma 127 Somatotroph adenoma 19 Peripheral nerve sheath tumours 128 Lactotroph adenoma 24 Benign vascular tumours 129 Thyrotroph adenoma 28 Angiosarcoma 129 Corticotroph adenoma 30 Smooth muscle tumours 132 Gonadotroph adenoma 34 Solitary fi brous tumour 133 Null cell adenoma 37 Haematolymphoid tumours 135 Plurihormonal and double adenomas 39 Langerhans cell histiocytosis 135 Pituitary carcinoma 41 Rosai–Dorfman disease 136 Pituitary blastoma 45 Follicular dendritic cell sarcoma 136 Craniopharyngioma 46 Primary thyroid lymphoma 137 Neuronal and paraneuronal tumours 48 Germ cell tumours 139 Gangliocytoma and mixed gangliocytoma–adenoma 48 Secondary tumours 142 Neurocytoma 49 Paraganglioma 50 3 Tumours of the parathyroid glands 145 Neuroblastoma 51 WHO classifi cation of tumours of the parathyroid glands 146 Tumours of the posterior pituitary 52 TNM staging of tumours of the parathyroid glands 146 Mesenchymal and stromal tumours 55 Parathyroid carcinoma 147 Meningioma 55 Parathyroid adenoma 153 Schwannoma 56 Secondary, mesenchymal and other tumours 159 Chordoma 57 Haemangiopericytoma / Solitary fi brous tumour 58 4 Tumours of the adrenal cortex 161 Haematolymphoid tumours 60 WHO classifi cation of tumours of the adrenal cortex 162 Germ cell tumours 61 TNM classifi
  • Cholangiocarcinoma 2020: the Next Horizon in Mechanisms and Management

    Cholangiocarcinoma 2020: the Next Horizon in Mechanisms and Management

    CONSENSUS STATEMENT Cholangiocarcinoma 2020: the next horizon in mechanisms and management Jesus M. Banales 1,2,3 ✉ , Jose J. G. Marin 2,4, Angela Lamarca 5,6, Pedro M. Rodrigues 1, Shahid A. Khan7, Lewis R. Roberts 8, Vincenzo Cardinale9, Guido Carpino 10, Jesper B. Andersen 11, Chiara Braconi 12, Diego F. Calvisi13, Maria J. Perugorria1,2, Luca Fabris 14,15, Luke Boulter 16, Rocio I. R. Macias 2,4, Eugenio Gaudio17, Domenico Alvaro18, Sergio A. Gradilone19, Mario Strazzabosco 14,15, Marco Marzioni20, Cédric Coulouarn21, Laura Fouassier 22, Chiara Raggi23, Pietro Invernizzi 24, Joachim C. Mertens25, Anja Moncsek25, Sumera Rizvi8, Julie Heimbach26, Bas Groot Koerkamp 27, Jordi Bruix2,28, Alejandro Forner 2,28, John Bridgewater 29, Juan W. Valle 5,6 and Gregory J. Gores 8 Abstract | Cholangiocarcinoma (CCA) includes a cluster of highly heterogeneous biliary malignant tumours that can arise at any point of the biliary tree. Their incidence is increasing globally, currently accounting for ~15% of all primary liver cancers and ~3% of gastrointestinal malignancies. The silent presentation of these tumours combined with their highly aggressive nature and refractoriness to chemotherapy contribute to their alarming mortality, representing ~2% of all cancer-related deaths worldwide yearly. The current diagnosis of CCA by non-invasive approaches is not accurate enough, and histological confirmation is necessary. Furthermore, the high heterogeneity of CCAs at the genomic, epigenetic and molecular levels severely compromises the efficacy of the available therapies. In the past decade, increasing efforts have been made to understand the complexity of these tumours and to develop new diagnostic tools and therapies that might help to improve patient outcomes.
  • Treatment Strategies for Hepatocellular Carcinoma—A Multidisciplinary Approach

    Treatment Strategies for Hepatocellular Carcinoma—A Multidisciplinary Approach

    International Journal of Molecular Sciences Review Treatment Strategies for Hepatocellular Carcinoma—A Multidisciplinary Approach Isabella Lurje 1,† , Zoltan Czigany 1,† , Jan Bednarsch 1, Christoph Roderburg 2,3, Peter Isfort 4, Ulf Peter Neumann 1,5 and Georg Lurje 1,* 1 Department of Surgery and Transplantation, University Hospital RWTH Aachen, 52074 Aachen, Germany; [email protected] (I.L.); [email protected] (Z.C.); [email protected] (J.B.); [email protected] (U.P.N.) 2 Department of Internal Medicine III, University Hospital RWTH Aachen, 52074 Aachen, Germany; [email protected] 3 Department of Gastroenterology/Hepatology, Campus Virchow Klinikum and Charité Mitte, Charité University Medicine Berlin, 13353 Berlin, Germany 4 Department for Diagnostic and Interventional Radiology, University Hospital RWTH Aachen, 52074 Aachen, Germany; [email protected] 5 Department of Surgery, Maastricht University Medical Centre (MUMC), 6229 ET Maastricht, The Netherlands * Correspondence: [email protected] † Both authors contributed equally to this work. Received: 9 March 2019; Accepted: 21 March 2019; Published: 22 March 2019 Abstract: Hepatocellular carcinoma (HCC) is the most common primary tumor of the liver and its mortality is third among all solid tumors, behind carcinomas of the lung and the colon. Despite continuous advancements in the management of this disease, the prognosis for HCC remains inferior compared to other tumor entities. While orthotopic liver transplantation (OLT) and surgical resection are the only two curative treatment options, OLT remains the best treatment strategy as it not only removes the tumor but cures the underlying liver disease. As the applicability of OLT is nowadays limited by organ shortage, major liver resections—even in patients with underlying chronic liver disease—are adopted increasingly into clinical practice.
  • Transarterial Chemoembolization with Radiofrequency Ablation Versus Hepatectomy in Hepatocellular Carcinoma Beyond the Milan Criteria: a Retrospective Study

    Transarterial Chemoembolization with Radiofrequency Ablation Versus Hepatectomy in Hepatocellular Carcinoma Beyond the Milan Criteria: a Retrospective Study

    Journal name: Cancer Management and Research Article Designation: Original Research Year: 2018 Volume: 10 Cancer Management and Research Dovepress Running head verso: Yuan et al Running head recto: TACE with RFA versus hepatectomy for HCC open access to scientific and medical research DOI: http://dx.doi.org/10.2147/CMAR.S182914 Open Access Full Text Article ORIGINAL RESEARCH Transarterial chemoembolization with radiofrequency ablation versus hepatectomy in hepatocellular carcinoma beyond the Milan criteria: a retrospective study Hang Yuan* Purpose: To compare the efficacies of transarterial chemoembolization (TACE) combined Ping Cao* with radiofrequency ablation (RFA) with hepatectomy. Prognostic factors for the patient groups Hai-Liang Li were analyzed. Hong-Tao Hu Patients and methods: Data of 314 newly diagnosed cases of hepatocellular carcinoma Chen-Yang Guo beyond the Milan criteria were studied from January 2012 to December 2013 in our hospital. Forty-four patients were excluded owing to loss to follow-up (27 cases) or missing imaging Yan Zhao data (17 cases); finally, 270 patients were included. All patients underwent TACE combined Quan-Jun Yao with RFA (TR group, 136 patients) or hepatectomy (HT group, 134 patients). Efficacy evalu- Xiang Geng ation and prognostic factor analysis of the groups were conducted. Overall survival (OS) rate, Minimally Invasive and Interventional progression-free survival (PFS) rate, and major complications were recorded. Department, Affiliated Cancer The 1-, 2-, 3-, and 5-year OS rates and median survival times were 98.5%, 83.1%, Hospital of Zhengzhou University, Results: Henan Cancer Hospital, Zhengzhou 66.2%, 37.1%, and 46 months, respectively, for the TR group and 89.6%, 69.4%, 53.7%, 450008, China 30.3%, and 38 months, respectively, for the HT group.
  • Time to Transplantation As Predictor of Hepatocellular Recurrence After Liver Transplantation: a Retrospective Cohort Study

    Time to Transplantation As Predictor of Hepatocellular Recurrence After Liver Transplantation: a Retrospective Cohort Study

    ARTÍCULO ORIGINAL Estudio retrospectivo Time to transplantation as predictor of hepatocellular recurrence after liver transplantation: a retrospective cohort study Santiago Rodriguez1, Lucas Ernani 2, Alfeu de Medeiros Fleck Jr.3 Claudio Augusto Marroni1,3, Ajacio Bandeira de Mello Brandão1,3 Este artículo está bajo una licencia de Creative Commons de tipo Recono- cimiento – No comercial – Sin obras derivadas 4.0 International 1 Graduate Program in Medicine: Hepatology. Univer- sidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre, RS, Brazil. Abstract 2 Department of Gastroenterology. Digestive System Surgery, School of Medicine, Hospital das Clínicas, Hepatocellular recurrence after liver transplantation (LTx) is a major cause Universidade de São Paulo (USP), São Paulo, SP, Brasil. 3 Liver Transplantation Group, Santa Casa de Miseri- of morbidity and mortality. We aimed to investigate the association córdia de Porto Alegre, Porto Alegre, RS, Brazil. between waiting time and hepatocellular carcinoma (HCC) recurrence in patients undergoing LTx for HCC. We studied 250 patients who ORCID ID: underwent LTx between 2007-2015. Survival and recurrence curves were Santiago Rodríguez. http://orcid.org/0000-0001-8610-3622 calculated according to the Kaplan–Meier method and compared by Lucas Ernani the log-rank test. Univariate hazard ratios for predictors of post-LTx HCC https://orcid.org/0000-0001-6570-8702 Claudio Augusto Marroni recurrence were determined by Cox proportional hazards regressions. https://orcid.org/0000-0002-1718-6548
  • Laparoscopic Resection of Hepatocellular Carcinoma: When, Why, and How? a Single-Center Experience

    Laparoscopic Resection of Hepatocellular Carcinoma: When, Why, and How? a Single-Center Experience

    JOURNAL OF LAPAROENDOSCOPIC & ADVANCED SURGICAL TECHNIQUES Volume 24, Number 4, 2014 ª Mary Ann Liebert, Inc. DOI: 10.1089/lap.2013.0502 Laparoscopic Resection of Hepatocellular Carcinoma: When, Why, and How? A Single-Center Experience Paulo Herman, MD, Marcos Vinicius Perini, MD, Fabricio Ferreira Coelho, MD, Jaime Arthur Pirolla Kruger, MD, Renato Micelli Lupinacci, MD, Gilton Marques Fonseca, MD, Felipe de Lucena Moreira Lopes, MD, and Ivan Cecconello, MD Abstract Purpose: The aim of this study was to evaluate short- and intermediate-term results of laparoscopic liver resection in selected patients with hepatocellular carcinoma (HCC). Patients and Methods: Eighty-five patients with HCC were subjected to liver resection between February 2007 and January 2013. From these, 30 (35.2%) were subjected to laparoscopic liver resection and were retro- spectively analyzed. Special emphasis was given to the indication criteria and to surgical results. Results: There were 21 males and 9 females with a mean age of 57.4 years. Patients were subjected to 10 nonanatomic and 20 anatomic resections. Two patients were subjected to hand-assisted procedures (right posterior sectionectomies); all other patients were subjected to totally laparoscopic procedures. Conversion to open surgery was necessary in 4 patients (13.3%). Postoperative complications were observed in 12 patients (40%), and the mortality rate was 3.3%. Mean overall survival was 29.8 months, with 3-year overall and disease-free survival rates of 76% and 58%, respectively. Conclusions: Laparoscopic treatment of selected patients with HCC is safe and feasible and can lead to good short- and intermediate-term results. Introduction organ needs.
  • (NCCN Guidelines®) Hepatobiliary Cancers

    (NCCN Guidelines®) Hepatobiliary Cancers

    NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Hepatobiliary Cancers Version 2.2015 NCCN.org Continue Version 2.2015, 02/06/15 © National Comprehensive Cancer Network, Inc. 2015, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®. Printed by Alexandre Ferreira on 10/25/2015 6:11:23 AM. For personal use only. Not approved for distribution. Copyright © 2015 National Comprehensive Cancer Network, Inc., All Rights Reserved. NCCN Guidelines Index NCCN Guidelines Version 2.2015 Panel Members Hepatobiliary Cancers Table of Contents Hepatobiliary Cancers Discussion *Al B. Benson, III, MD/Chair † Renuka Iyer, MD Þ † Elin R. Sigurdson, MD, PhD ¶ Robert H. Lurie Comprehensive Cancer Roswell Park Cancer Institute Fox Chase Cancer Center Center of Northwestern University R. Kate Kelley, MD † ‡ Stacey Stein, MD, PhD *Michael I. D’Angelica, MD/Vice-Chair ¶ UCSF Helen Diller Family Yale Cancer Center/Smilow Cancer Hospital Memorial Sloan Kettering Cancer Center Comprehensive Cancer Center G. Gary Tian, MD, PhD † Thomas A. Abrams, MD † Mokenge P. Malafa, MD ¶ St. Jude Children’s Dana-Farber/Brigham and Women’s Moffitt Cancer Center Research Hospital/ Cancer Center The University of Tennessee James O. Park, MD ¶ Health Science Center Fred Hutchinson Cancer Research Center/ Steven R. Alberts, MD, MPH Seattle Cancer Care Alliance Mayo Clinic Cancer Center Jean-Nicolas Vauthey, MD ¶ Timothy Pawlik, MD, MPH, PhD ¶ The University of Texas Chandrakanth Are, MD ¶ The Sidney Kimmel Comprehensive MD Anderson Cancer Center Fred & Pamela Buffett Cancer Center at Cancer Center at Johns Hopkins The Nebraska Medical Center Alan P.
  • Continuous Improvement of Survival Outcomes of Resection of Hepatocellular Carcinoma: a 20-Year Experience

    Continuous Improvement of Survival Outcomes of Resection of Hepatocellular Carcinoma: a 20-Year Experience

    Continuous improvement of survival outcomes of resection of hepatocellular carcinoma: a 20-year experience (ANNSURG-D-10-00234.R2) Sheung Tat FAN MS, MD, PhD, DSc, FRCS (Glasg & Edin), FACS Chung Mau LO MS, FRCS (Edin), FACS Ronnie T.P. POON MS, PhD, FRCS (Edin), FACS Chun YEUNG MBBS, FRCS (Glasg), FACS Chi Leung LIU MBBS, MS, MD, FRCS (Edin), FACS Wai Key YUEN MBBS, FRCS (Glasg), FRACS (Gen Surg), FACS Chi Ming LAM MBBS, MS, PhD, FRCS (Edin) Kelvin K.C. NG MS, PhD, FRCSEd (Gen) See Ching CHAN MS, FRCS (Edin) Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Pok Fu Lam Road, Hong Kong Correspondence to: Professor Sheung Tat FAN Department of Surgery The University of Hong Kong Queen Mary Hospital 102 Pok Fu Lam Road Hong Kong Tel: (852) 2255 4703 Fax: (852) 2986 5262 Email: [email protected] Keywords: Hepatocellular carcinoma, hepatectomy, hospital mortality, survival rates Short title: Survival outcomes of resection of hepatocellular carcinoma Mini-Abstract A continuous improvement of the survival results of hepatectomy for hepatocellular carcinoma was observed in the past 20 years. The improvement was seen in patients with cirrhosis, those undergoing major hepatectomy, and those with liver tumors of TNM stages II, IIIA and IVA. Structured Abstract Objective: To investigate the trend of the post-hepatectomy survival outcomes of hepatocellular carcinoma (HCC) patients by analysis of a prospective cohort of 1198 patients over a 20-year period. Summary Background Data: The hospital mortality rate of hepatectomy for HCC has improved but the long-term survival rate remains unsatisfactory.
  • Neuroendocrine Tumors of the Pancreas (Including Insulinoma, Gastrinoma, Glucogacoma, Vipoma, Somatostatinoma)

    Neuroendocrine Tumors of the Pancreas (Including Insulinoma, Gastrinoma, Glucogacoma, Vipoma, Somatostatinoma)

    Neuroendocrine tumors of the pancreas (including insulinoma, gastrinoma, glucogacoma, VIPoma, somatostatinoma) Neuroendocrine pancreatic tumors (pancreatic NETs or pNETs) account for about 3% of all primary pancreatic tumors. They develop in neuroendocrine cells called islet cells. Neuroendocrine tumors of the pancreas may be nonfunctional (not producing hormones) or functional (producing hormones). Most pNETs do not produce hormones and, as a result, these tumors are diagnosed incidentally or after their growth causes symptoms such as abdominal pain, jaundice or liver metastasis. pNETs that produce hormones are named according to the type of hormone they produce and / or clinical manifestation: Insulinoma - An endocrine tumor originating from pancreatic beta cells that secrete insulin. Increased insulin levels in the blood cause low glucose levels in blood (hypoglycemia) with symptoms that may include sweating, palpitations, tremor, paleness, and later unconsciousness if treatment is delayed. These are usually benign and tend to be small and difficult to localize. Gastrinoma - a tumor that secretes a hormone called gastrin, which causes excess of acid secretion in the stomach. As a result, severe ulcerative disease and diarrhea may develop. Most gastrinomas develop in parts of the digestive tract that includes the duodenum and the pancreas, called "gastrinoma triangle". These tumors have the potential to be malignant. Glucagonoma is a rare tumor that secretes the hormone glucagon, which may cause a typical skin rash called migratory necrolytic erythema, elevated glucose levels, weight loss, diarrhea and thrombotic events. VIPoma - a tumor that secretes Vasoactive peptide (VIP) hormone causing severe diarrhea. The diagnosis is made by finding a pancreatic neuroendocrine tumor with elevated VIP hormone in the blood and typical clinical symptoms.
  • Primary Hepatic Carcinoid Tumor with Poor Outcome Om Parkash Aga Khan University, Om.Parkash@Aku.Edu

    Primary Hepatic Carcinoid Tumor with Poor Outcome Om Parkash Aga Khan University, [email protected]

    eCommons@AKU Section of Gastroenterology Department of Medicine March 2016 Primary Hepatic Carcinoid Tumor with Poor Outcome Om Parkash Aga Khan University, [email protected] Adil Ayub Buria Naeem Sehrish Najam Zubair Ahmed Aga Khan University See next page for additional authors Follow this and additional works at: https://ecommons.aku.edu/ pakistan_fhs_mc_med_gastroenterol Part of the Gastroenterology Commons Recommended Citation Parkash, O., Ayub, A., Naeem, B., Najam, S., Ahmed, Z., Jafri, W., Hamid, S. (2016). Primary Hepatic Carcinoid Tumor with Poor Outcome. Journal of the College of Physicians and Surgeons Pakistan, 26(3), 227-229. Available at: https://ecommons.aku.edu/pakistan_fhs_mc_med_gastroenterol/220 Authors Om Parkash, Adil Ayub, Buria Naeem, Sehrish Najam, Zubair Ahmed, Wasim Jafri, and Saeed Hamid This report is available at eCommons@AKU: https://ecommons.aku.edu/pakistan_fhs_mc_med_gastroenterol/220 CASE REPORT Primary Hepatic Carcinoid Tumor with Poor Outcome Om Parkash1, Adil Ayub2, Buria Naeem2, Sehrish Najam2, Zubair Ahmed, Wasim Jafri1 and Saeed Hamid1 ABSTRACT Primary Hepatic Carcinoid Tumor (PHCT) represents an extremely rare clinical entity with only a few cases reported to date. These tumors are rarely associated with metastasis and surgical resection is usually curative. Herein, we report two cases of PHCT associated with poor outcomes due to late diagnosis. Both cases presented late with non-specific symptoms. One patient presented after a 2-week history of symptoms and the second case had a longstanding two years symptomatic interval during which he remained undiagnosed and not properly worked up. Both these cases were diagnosed with hepatic carcinoid tumor, which originates from neuroendocrine cells. Case 1 opted for palliative care and expired in one month’s time.
  • Liver Transplantation for Hepatocellular Carcinoma: a Real-Life Comparison of Milan Criteria and AFP Model

    Liver Transplantation for Hepatocellular Carcinoma: a Real-Life Comparison of Milan Criteria and AFP Model

    cancers Article Liver Transplantation for Hepatocellular Carcinoma: A Real-Life Comparison of Milan Criteria and AFP Model Bleuenn Brusset 1,2, Jerome Dumortier 3, Daniel Cherqui 4, Georges-Philippe Pageaux 5, Emmanuel Boleslawski 6 , Ludivine Chapron 2, Jean-Louis Quesada 2 , Sylvie Radenne 7, Didier Samuel 4, Francis Navarro 5, Sebastien Dharancy 6 and Thomas Decaens 1,2,8,* 1 Faculty of Medicine, University Grenoble-Alpes, 38000 Grenoble, France; [email protected] 2 CHU Grenoble-Alpes, 38000 Grenoble, France; [email protected] (L.C.); [email protected] (J.-L.Q.) 3 Hospices Civiles de Lyon, Hôpital Edouard Herriot, 69003 Lyon, France; [email protected] 4 Assistance Publique des Hôpitaux de Paris, Hôpital Paul Brousse, Centre Hépato-Biliaire, 94800 Villejuif, France; [email protected] (D.C.); [email protected] (D.S.) 5 CHU de Montpellier, 34295 Montpellier, France; [email protected] (G.-P.P.); [email protected] (F.N.) 6 CHU de Lille, 59000 Lille, France; [email protected] (E.B.); [email protected] (S.D.) 7 Hospices Civiles de Lyon, Hôpital de la Croix Rousse, 69004 Lyon, France; [email protected] 8 Institute for Advanced Biosciences, Research Center UGA/Inserm U 1209/CNRS 5309, 38000 Grenoble, France Citation: Brusset, B.; Dumortier, J.; * Correspondence: [email protected]; Tel.: +33-4-7676-5441 Cherqui, D.; Pageaux, G.-P.; Boleslawski, E.; Chapron, L.; Simple Summary: The α-fetoprotein (AFP) model officially replaced the Milan criteria in France Quesada, J.-L.; Radenne, S.; Samuel, for liver transplantation (LT) for hepatocellular carcinoma (HCC) in January 2013.
  • Surgical Management of Ampullary Somatostatinoma

    Surgical Management of Ampullary Somatostatinoma

    JOP. J Pancreas (Online) 2016 Jul 08; 17(4):406-409. CASE SERIES Surgical Management of Ampullary Somatostatinoma Nicholas Phillips, Terence Huey, Joel Lewin, Anthony W Cheng, Nicholas A O’Rourke Hepato-Pancreato-Biliary Unit, Department of General Surgery, Royal Brisbane Hospital, Brisbane, Australia ABSTRACT Introduction Somatostatinomas of the ampulla are rare neuroendocrine tumours with limited studies in the literature. These are often associated with familial genetic predisposition e.g. NF 1 and Von Hippel-Lindau Syndrome. Histology commonly shows classical features such as Psammoma bodies. The classical presentation with inhibitory syndrome is rare, but ampullary mass effects can cause an earlier presentation with potentially better outcomes with earlier intervention and treatment. Case series We report three cases of ampullary the second with recurrent pancreatitis and the third, with elevated CA19-9 levels. Various preoperative localisation techniques were employedsomatostatisnomas: and one had one an sporadic attempted and endoscopic two familial, resection associated yielding with involved neurofibromatosis margins. All type patients 1. The underwent first patient pancreaticoduodenectomy, presented with pruritus, of which one was laparoscopic assisted. The median size of the tumour was 10 mm and one patient had nodal involvement. All 3 patients have remained disease free at most recent follow up ranging from 1.5 to 11 years. Discussion Ampullary somatostatinomas can present early with mass related effects while inhibitory syndrome is rare. Early detection and intervention in ampullary somatostatinoma may contribute to better outcomes than pancreatic somatostatinomas. Long-term survival is achievable through pancreaticoduodenectomy for resectable ampullary somatostatinoma and laparoscopic approach is a feasible and viable option. INTRODUCTION cases of ampullary somatostatinoma that were treated by pancreaticoduodenectomy (PD) with good outcomes.